New Drug Approved for Early Alzheimer’s - The New York Times
WEBJul 2, 2024 · The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
FDA approves a second Alzheimer's drug, Eli Lilly's Kisunla - AP News
WEBJul 2, 2024 · The FDA approved Kisunla, known chemically as donanemab, based on results from an 18-month study in which patients given getting the treatment declined about 22% more slowly in terms of memory and cognitive ability than those who received a dummy infusion.
News Release - Eli Lilly and Company
WEBJul 2, 2024 · Kisunla is the first and only amyloid plaque-targeting therapy that used a limited-duration treatment regimen based on amyloid plaque removal; nearly half of study participants completed their course of treatment with Kisunla in 12 months.
FDA Approves Kisunla (Donanemab) | Alzheimer's Association
WEBCHICAGO, July 2, 2024 — The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to approve Kisunla™ (donanemab, Eli Lilly) for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease ...
Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the …
WEB5 days ago · Kisunla™ (donanemab-azbt), pronounced kih-SUHN-lah, is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.
FDA approves a second Alzheimer's drug that can modestly slow …
WEBJul 3, 2024 · The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer’s. It’s only the second drug that’s been convincingly shown to...
FDA approves treatment for adults with Alzheimer’s disease
WEBJul 2, 2024 · The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild...
FDA approves donanemab, Eli Lilly’s treatment for early ... - CNN
WEBJul 2, 2024 · Kisunla is not the first monoclonal antibody treatment approved to treat early Alzheimer’s. Eisai and Biogen’s lecanemab, sold as Leqembi, is already being used.
FDA approves 2nd Alzheimer’s drug that can modestly slow …
WEBJul 2, 2024 · The FDA approved Kisunla, known chemically as donanemab, based on results from an 18-month study in which patients given getting the treatment declined about 22 percent more slowly in terms of...
FDA approves treatment for adults with Alzheimer’s disease
WEBThe U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials.